Page last updated: 2024-12-10

(4-methylphenyl)-(10-phenothiazinyl)methanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

(4-Methylphenyl)-(10-phenothiazinyl)methanone, also known as **chlorpromazine**, is a **phenothiazine antipsychotic drug**. It's **not** just a research chemical; it's a widely used medication for the treatment of **schizophrenia** and other mental disorders. Here's why it's important:

* **Historical Significance:** Chlorpromazine was the first antipsychotic drug to be developed and introduced in 1952. It revolutionized the treatment of severe mental illnesses like schizophrenia.
* **Mechanism of Action:** Chlorpromazine acts as a **dopamine receptor antagonist**. This means it blocks the effects of dopamine, a neurotransmitter involved in mood, motivation, and movement. By reducing dopamine activity in the brain, chlorpromazine helps alleviate the symptoms of psychosis, such as hallucinations and delusions.
* **Clinical Uses:** Chlorpromazine is used to treat:
* **Schizophrenia:** It effectively reduces positive symptoms like hallucinations and delusions.
* **Mania:** It can be used to manage episodes of mania in bipolar disorder.
* **Severe anxiety:** Chlorpromazine can be used to reduce anxiety in patients with severe anxiety disorders.
* **Nausea and vomiting:** It can also be used to treat nausea and vomiting related to surgery, chemotherapy, or other medical conditions.
* **Research Interest:** Despite being widely used, there's still active research interest in chlorpromazine:
* **New Indications:** Research is ongoing to explore its potential use in other conditions, such as obsessive-compulsive disorder and Alzheimer's disease.
* **Mechanism of Action:** Studies aim to better understand how chlorpromazine interacts with specific brain receptors and pathways.
* **Drug Delivery:** Researchers are exploring new drug delivery methods for chlorpromazine to improve its effectiveness and reduce side effects.

While chlorpromazine is a valuable medication, it has potential side effects like drowsiness, dizziness, and weight gain. It's essential to discuss the risks and benefits with your healthcare provider before taking chlorpromazine or any other medication.

Cross-References

ID SourceID
PubMed CID3473393
CHEMBL ID397100
CHEBI ID93656

Synonyms (12)

Synonym
OPREA1_194230
CHEMBL397100 ,
smr001537727
MLS002608923
(10h-phenothiazin-10-yl)(p-tolyl)methanone
cid_3473393
bdbm50219212
BRD-K94919853-001-01-9
(4-methylphenyl)-phenothiazin-10-ylmethanone
CHEBI:93656
Q27165345
(4-methylphenyl)-(10-phenothiazinyl)methanone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenothiazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency35.48130.058010.694926.6086AID602310
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)46.54100.06008.9128130.5170AID2137
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID300872Inhibition of human plasma BuChE activity2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
AID300873Inhibition of recombinant human AChE activity2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]